Maricann Group (CNSX:MARI – Free Report) had its price objective lifted by Canaccord Genuity Group from $6.00 to $7.50 in a research note issued to investors on Monday, BayStreet.CA reports.
Separately, Raymond James lifted their target price on shares of Maricann Group from $6.00 to $6.50 in a research note on Tuesday, April 23rd.
Check Out Our Latest Research Report on Maricann Group
Maricann Group Price Performance
About Maricann Group
Maricann Group Inc, formerly Danbel Industries Corporation, is a Canada-based integrated producer and distributor of marijuana for medical purposes. As one of approximately 43 companies with a federal license to cultivate cannabis and one of approximately 30 independent licensed producers with a federal license to process and distribute cannabis, the Company’s services a patient base with more than 8,000 registered patients.
Recommended Stories
- Five stocks we like better than Maricann Group
- Pros And Cons Of Monthly Dividend Stocks
- Food Processing Company Stock Gets Fried by Recall: Time to Buy
- What are earnings reports?
- Entertainment Stock Offers A Rare and Tempting Entry Opportunity
- Why Invest in 5G? How to Invest in 5G Stocks
- Will China’s Interest Rate Cuts Ignite a Rally for This Stock?
Receive News & Ratings for Maricann Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maricann Group and related companies with MarketBeat.com's FREE daily email newsletter.
